trending Market Intelligence /marketintelligence/en/news-insights/trending/okuzvu6rlbhqfrhg4hzhsg2 content esgSubNav
In This List

AVEO names director

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


AVEO names director

AVEO Pharmaceuticals Inc. appointed John Johnson as a director.

Johnson is the chairman of Strongbridge Biopharma plc and has previously served as chairman of Tranzyme Pharma Inc. and as chairman, president and CEO of Dendreon Corp. and as CEO and a board member of Savient Pharmaceuticals Inc.

In addition, Johnson has held commercial and executive management roles at global corporations that have a focus on oncology, including Johnson & Johnson, Eli Lilly and Co. and Pfizer Inc.